Search Results
Your search for Blood matches 4802 pages
Showing 4501 - 4550FDA Approves Palbociclib in Combination With Letrozole for Advanced Breast Cancer
The U.S. Food and Drug Administration has granted accelerated approval to palbociclib (Ibrance) in combination with letrozole for the treatment of postmenopausal women with estrogen receptor–positive, HER2-negative metastatic breast cancer who have not yet received an endocrine-based therapy. ...
Study Finds Biologic Markers Associated With High-Risk Pancreatic Lesions
Pancreatic cancer affects approximately 46,000 people each year in the United States, and ranks fourth among the leading causes of cancer-related deaths. Only about 6% of individuals with pancreatic cancer will live 5 years after their diagnosis. One reason for this high mortality rate is the lack...
Ibrutinib Active in Previously Untreated and Relapsed/Refractory CLL With TP53 Aberrations
In a phase II study reported in The Lancet Oncology, Farooqui et al found that single-agent ibrutinib (Imbruvica) had good activity in patients with previously untreated or relapse/refractory chronic lymphocytic leukemia (CLL) with TP53 aberrations. Study Details In this single-arm trial, 51...
Protein-Based Therapy Shows Promise Against Resistant ALL in Preclinical Study
Chemotherapy resistance is one of the most formidable obstacles to treating acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Now researchers at Children’s Hospital Los Angeles (CHLA) have designed and developed a new protein-based therapy that may prove highly...
Testosterone Therapy May Help Some Men With Castration-Resistant Prostate Cancer
According to researchers at the Johns Hopkins Kimmel Cancer Center, testosterone, which is generally thought to be a feeder of prostate cancer, has been found to suppress some advanced prostate cancers. The hormone may also reverse resistance to testosterone-blocking drugs used to treat prostate...
Supplemental New Drug Application Submitted for Carfilzomib for Relapsed Multiple Myeloma
Amgen and its subsidiary Onyx Pharmaceuticals, Inc, announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for carfilzomib (Kyprolis) to seek approval for the treatment of patients with relapsed multiple myeloma who have received at...
Age-Related Clonal Hematopoiesis Associated With Increased Risk of All-Cause Mortality, Heart Disease, and Stroke, as Well as Blood Cancer
In a study reported in The New England Journal of Medicine, Jaiswal et al found somatic mutations associated with hematologic cancers at increasing frequency with increasing age, with presence of the mutations being associated with increased risk of hematologic cancers, all-cause mortality,...
Clonal Hematopoiesis With Somatic Mutations Increases With Age and Increases Risk of Hematologic Cancer and Mortality
In a study reported in The New England Journal of Medicine, Genovese et al found that clonal hematopoiesis with somatic mutations is increasingly common with greater age and is associated with increased risk of hematologic cancer. The presence of such clonal hematopoiesis in apparently healthy...
TP53 Mutations May Play a Role in Treatment‑Related Acute Myeloid Leukemia and Myelodysplastic Syndrome
A genomic study of cancer patients previously treated with chemotherapy or radiation therapy found that TP53 mutations may play a role in the development of treatment-related acute myeloid leukemia (AML) and myelodysplastic syndrome, according to a report by Wong et al in Nature. However, the...
ATRX Mutation Linked to Brain and Pancreatic Neuroendocrine Tumors May Be Biomarker for Rare Adrenal Tumors
A somatic mutation in the ATRX gene has recently been identified as a potential molecular marker for gliomas, neuroblastomas, and pancreatic neuroendocrine tumors. Now, researchers at the Perelman School of Medicine at the University of Pennsylvania have found that the same mutated gene may serve...
Modified Pancreatic Cancer Regimen Maintains Effectiveness While Reducing Side Effects and Cost
A simple change to a two-drug therapy for metastatic pancreatic cancer provides similar cancer control while significantly improving quality of life and reducing the cost of care, according to data reported by researchers at the The Ohio State University Comprehensive Cancer Center – Arthur...
Metabolic Syndrome Linked With Higher Risk of Endometrial Cancer Regardless of Being Overweight or Obese
A large population-based analysis of women 65 and older in the United States diagnosed with endometrial cancer has found that women with metabolic syndrome—characterized by low HDL cholesterol, hypertension, high triglycerides, and elevated waist circumference—have an increased risk of...
Combining Newer, More Intensive First-Line Chemotherapy With Bevacizumab Improves Long-Term Outcome in Advanced Colorectal Cancer
Updated results from TRIBE, an Italian phase III study of patients with metastatic colorectal cancer, indicate that FOLFOXIRI (leucovorin, fluorouracil [5-FU], oxaliplatin, irinotecan) chemotherapy in combination with bevacizumab (Avastin) is superior to the standard FOLFIRI (leucovorin, 5-FU,...
Higher Vitamin D Levels Associated With Markedly Improved Survival in Patients With Advanced Colorectal Cancer
A prospective analysis of data from a phase III study of patients newly diagnosed with metastatic colorectal cancer indicates that patients with higher vitamin D levels have better outcomes after treatment with chemotherapy and targeted therapy. The median overall survival for patients with the...
New Cancer Diagnoses Associated With Increased Risk of Stroke
Patients with new cases of cancer face a heightened risk of stroke in the months immediately following their diagnoses, with that risk escalating with the aggressiveness of their disease, according to a new study from researchers at Weill Cornell Medical College and Memorial Sloan Kettering Cancer...
Study Finds Whole-Genome Sequencing Is Successful in Identifying Patients’ Risk for Inherited Cancers
After performing whole-genome sequencing on patients found to have BRCA1or BRCA2 mutations as well as on those that were not carriers of either mutation, researchers found cancer risk–related potentially pathogenic variants in those without BRCA mutations. While the results highlight the ...
Bispecific CD19-Directed CD3 T-Cell Engager Blinatumomab Active in Adults With Relapsed/Refractory B-Cell Precursor ALL
In a phase II study reported in The Lancet Oncology, Topp et al found that the bispecific CD19-directed CD3 T-cell engager (BiTE) blinatumomab (Blincyto) was highly active in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab binds to CD19 expressed ...
Somatic Tumor Neoepitopes as Basis for Response to CTLA-4 Inhibition in Melanoma
The molecular determinants of benefit from immune checkpoint inhibitor treatment have not been characterized. In a study reported in The New England Journal of Medicine, Snyder et al found that benefit of the anti–cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibodies ipilimumab (Yervoy) and...
FDA Approves Companion Diagnostic for the Detection of BRCA1/2 Mutations in Ovarian Cancer
Today’s approval by the U.S. Food and Drug Administration (FDA) of olaparib (Lynparza) occurred concurrently with that of a companion diagnostic, BRACAnalysis CDx. This genetic test is designed to detect the presence of mutations in the BRCA genes in blood samples from patients with ovarian...
FDA Approves Olaparib to Treat BRCA-Mutated Advanced Ovarian Cancer
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to olaparib (Lynparza) for women with advanced ovarian cancer with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer, as detected by an FDA-approved test, who have been treated with three ...
ASH 2014: Pracinostat Combination Shows Significant Clinical Activity in Phase II Study of Newly Diagnosed Acute Myeloid Leukemia
In a phase II study, the histone deacetylase inhibitor pracinostat demonstrated significant clinical activity in combination with azacitadine in elderly patients with newly diagnosed acute myeloid leukemia (AML). Interim data from 33 evaluable patients were presented at the 56th American Society of ...
ASH 2014: Oral Inhibitor Shows Clinical Activity in Poor-Prognosis AML
An oral targeted drug has shown encouraging activity and tolerable side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML), a poor-prognosis group with few options, reported investigators from Dana-Farber Cancer Institute and The University of Texas MD...
ASH 2014: Common Genetic Variations May Contribute to Treatment-Related Cognitive Problems in Children With Leukemia
Common variations in four genes related to brain inflammation or cells′ response to damage from oxidation may contribute to the problems with memory, learning, and other cognitive functions seen in children treated for acute lymphoblastic leukemia (ALL), according to a study presented at the...
ASH 2014: T-Cell Acute Lymphoblastic Leukemia Outcomes Excellent, Even for 'Poor-Risk' Group
Outcomes in children with T-cell acute lymphoblastic leukemia (ALL), which has traditionally been considered a poor-prognosis cancer, are better than expected, even for the early thymic precursor (ETP) phenotype, according to investigators from the Children’s Oncology Group (COG) who...
ASH 2014: High Hopes for AG-221 in Advanced Leukemia
Although the data are preliminary, single-agent AG-221 therapy targeted to the IDH2 mutation holds great promise as a nonchemotherapy approach for the treatment of advanced hematologic malignancies, including relapsed/refractory acute myelogenous leukemia (AML) and untreated AML. The findings were...
ASH 2014: Combination Therapy Shown to Be Effective for Patients With Myelodysplastic Syndrome and AML
A phase II study investigating the potential of the drugs azacitidine and lenalidomide (Revlimid) demonstrated that the two therapies in combination may be an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia (AML). The...
ASH 2014: CD19-Directed CAR T-Cell Therapy Yields High Rate of Durable Remissions in Pediatric Acute Lymphoblastic Leukemia
As more experience is gained with the use of genetically engineered chimeric antigen receptor (CAR) T cells in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL), the data continue to be highly encouraging. To date, 36 of 39 pediatric ALL patients (92%) treated with...
ASH 2014: Pediatric Leukemia Treatment Regimens Lead to Improved Outcomes in Adolescents, Young Adults
Results from a large prospective study suggest that children and young adults with acute lymphocytic leukemia (ALL) may respond better to a chemotherapy regimen pioneered in pediatric patients. The findings were presented at the 56th American Society of Hematology (ASH) Annual Meeting and...
ASH 2014: HIV-Related Lymphoma Can Be Safely Treated With Autologous Hematopoietic Cell Transplant
Patients with human immunodeficiency virus (HIV)-related relapsed/refractory lymphoma can safely undergo autologous hematopoietic cell transplant, according to results of a phase II multicenter trial. At many centers, patients with HIV-related lymphoma are currently excluded from this potentially...
FDA Approves Ruxolitinib to Treat Patients With Polycythemia Vera
The U.S. Food and Drug Administration (FDA) today approved a new use for ruxolitinib (Jakafi) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Ruxolitinib, a JAK inhibitor, is the first drug approved by the FDA for this condition. Polycythemia vera occurs when too...
Addition of Vosaroxin to Cytarabine Demonstrates Antileukemic Activity in Relapsed or Refractory Acute Myeloid Leukemia
In a phase Ib/II study of patients with relapsed or refractory acute myeloid leukemia (AML), the addition of vosaroxin to cytarabine demonstrated antileukemic activity and an acceptable risk-benefit profile, according to a study by Lancet et al in Haematologica. Based on the findings from this...
Two- vs One-Unit Cord Blood Transplantation Does Not Improve 1-Year Overall Survival in Children and Adolescents With Hematologic Cancers
In a phase III trial reported in The New England Journal of Medicine, Wagner et al found that use of two units vs one unit of umbilical cord blood in hematopoietic stem cell transplantation did not improve 1-year overall survival in children and adolescents with hematologic cancers. Use of...
Immune Checkpoint Inhibitors May Work in Brain Cancers
New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today at the ESMO Symposium on Immuno-Oncology 2014 in Geneva (Abstract 1O). The novel research shows that brain metastases of tumor infiltrating lymphocytes, providing an immunoactive...
Galeterone Shows Activity in Variant Form of Castration-Resistant Prostate Cancer
Results from the ARMOR2 of the anticancer drug galeterone shows that it is successful in lowering prostate-specific antigen (PSA) levels in men with a variant form castration-resistant prostate cancer. The findings, presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer...
Patients With Advanced Papillary Kidney Cancer Respond Well to Bevacizumab/Erlotinib Combination Therapy
Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anticancer drugs. The combination of bevacizumab (Avastin) and erlotinib (Tarceva) produced excellent...
IDH1 Inhibitor Demonstrates Anticancer Activity in Advanced Leukemia
A phase I trial of the first drug designed to inhibit the cancer-causing activity of a mutated enzyme known as isocitrate dehydrogenase (IDH) 1, which is involved in cell metabolism, has shown clinical activity in patients with advanced acute myeloid leukemia (AML) with the IDH1 mutation. The...
Oncology Advances Included in Cleveland Clinic's Top 10 Medical Innovations List for 2015
Antibody-drug conjugates, checkpoint inhibitors, and single-dose intraoperative radiation therapy for breast cancer were included in the Cleveland Clinic's Ninth Annual Top 10 Medical Innovations List released earlier today. The list identifies those advances likely to have a major impact on...
Loss of Y Chromosome Associated With Higher Mortality and Risk of Cancer in Men
Age-related loss of the Y chromosome from blood cells, a frequent occurrence among elderly men, is associated with elevated risk of various cancers and earlier death, according to research presented at the American Society of Human Genetics 2014 Annual Meeting in San Diego (Abstract 295). This...
Blood Biomarker May Detect Lung Cancer
A new study shows that patients with stage I to III non–small cell lung cancer have different metabolite profiles in their blood than those of patients who are at risk but do not have lung cancer. The study abstract was released today in an online supplement to the journal CHESTand will be...
CD19-Directed CAR T Cells Produce Sustained Remission in Relapsed/Refractory ALL
In a study reported in The New England Journal of Medicine, Maude et al reported achieving sustained remissions in children and adults with relapsed/refractory acute lymphoblastic leukemia (ALL) using autologous CD19-targeted chimeric antigen receptor (CAR)-modified T cells. Study Details In the...
Substantial Benefit of Intensive Surveillance Following Bimodality Therapy for Esophageal Cancer
In a study reported in the Journal of Clinical Oncology, Sudo et al found that many patients undergoing definitive chemoradiotherapy (bimodality therapy) for esophageal cancer can derive substantial survival benefit from subsequent salvage surgery, supporting a practice of intensive...
Updated GEM2005 Trial Confirms Benefit of Melphalan/Bortezomib Combination in Elderly Multiple Myeloma Patients
Melphalan in combination with bortezomib (Velcade) should be maintained as one of the standards of care for the treatment of elderly patients with multiple myeloma, concluded Spanish trialists reporting updated results from the GEM2005 study comparing bortezomib/melphalan/prednisone with...
Higher Levels of Cholesterol and Triglycerides May Increase the Risk of Prostate Cancer Recurrence
Prostate cancer survivors with higher levels of total cholesterol and triglycerides had an increased risk for disease recurrence, according to a study by Allott et al. The study findings, coupled with evidence that statin use is associated with reduced recurrence risk, suggest that lipid levels...
New Mutations Found in Anaplastic Thyroid Cancer Lead to Dramatic Response and Acquired Resistance to Everolimus
A study involving a patient with metastatic anaplastic thyroid cancer who achieved a near-complete response to everolimus (Afinitor) that lasted for 18 months, followed by progressive disease, has revealed a previously unknown mutation in the TSC2 gene and in the mTOR protein. The discovery...
No Increased Risk of Ovarian Cancer With Perineal Powder Use
Perineal powder use has been associated with increased risk of ovarian cancer in case-control studies and with increased risk of serous invasive ovarian cancer in a cohort study. In a large cohort study reported in the Journal of the National Cancer Institute, Houghton et al found no significant...
Sex Steroid Hormones May Play a Role in the Development of Aggressive Prostate Cancer
Men with higher estradiol-to-testosterone ratios had a substantially reduced risk of aggressive prostate cancer, whereas men with higher ratios of 2-hydroxyestrone to 16α-hydroxyestrone had an increased risk of such cancer, according to the study findings presented by Black et al in Cancer...
ESMO 2014: Adding Cediranib to Chemotherapy Improves Progression-Free Survival in Metastatic or Recurrent Cervical Cancer
For patients with recurrent or metastatic cervical cancer, adding the experimental drug cediranib to standard chemotherapy improved tumor shrinkage and resulted in a modest improvement in progression-free survival, researchers reported at the ESMO 2014 Congress in Madrid (Abstract LBA25_PR). In...
Boost in Plasma Levels of Chain Amino Acids Is Associated With Increased Risk of Pancreatic Cancer
In a recent study reported in Nature Medicine, scientists from Dana-Farber Cancer Institute, the Massachusetts Institute of Technology, and the Harvard School of Public Health, among other institutions, investigated whether pancreatic ductal adenocarcinoma produces metabolic changes that can be...
Clinical Trials Investigate Treatment Options for Precursor Diseases to Multiple Myeloma
The availability of newer agents that have transformed treatment outcomes in multiple myeloma has naturally led to interest in studying these drugs earlier in precursor states, such as monoclonal gammopathy of undetermined significance and smoldering myeloma. Recent evidence suggests that this may...
Preclinical Study Identifies Potential Drug Combination for Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
Combining the molecular targeted drug ibrutinib (Imbruvica) with the investigational anticancer agent ABT-199 may improve outcomes for patients with mantle cell lymphoma and chronic lymphocytic leukemia (CLL), according to preclinical data presented at the American Association for Cancer Research...
